Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings. We have evaluated the effectiveness of different factor concentrates at reversing modifications of...
Guardado en:
Autores principales: | Gines Escolar, Victor Fernandez-Gallego, Eduardo Arellano-Rodrigo, Jaume Roquer, Joan Carles Reverter, Victoria Veronica Sanz, Patricia Molina, Irene Lopez-Vilchez, Maribel Diaz-Ricart, Ana Maria Galan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ba1054d50e164e1788406256ef70c447 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Features of reaction of coagulation hemostasis in children with pneumonia
por: N. A. Dorokhov, et al.
Publicado: (2016) -
Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study
por: Bruce Cartwright, et al.
Publicado: (2021) -
Clinical Significance and Prognostic Value of Hemostasis Parameters in 337 Patients with Acute Infective Endocarditis
por: Rosa Zampino, et al.
Publicado: (2021) - Seminars in thrombosis and hemostasis
-
NFκB in the development of endothelial activation and damage in uremia: an in vitro approach.
por: Carolina Caballo, et al.
Publicado: (2012)